Credit: Shutterstock The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to a promising new treatment for dry age-related macular degeneration (AMD)—a leading cause of vision loss. The therapy is being developed by Luxa Biotechnology and supported in part by the California Institute for Regenerative Medicine (CIRM). What RMAT Designation Means RMAT designation … Continue reading Luxa Biotechnology’s CIRM-funded Dry AMD Therapy Milestone
Luxa Biotechnology
Advancing cell therapy research for dry age-related macular degeneration (dry AMD)
The California Institute for Regenerative Medicine (CIRM) awarded Luxa Biotechnology $4 million to support the Phase 1/2a study (NCT04627428) of RPESC‑RPE‑4W transplantation, an innovative therapy for dry age‑related macular degeneration. The funding will significantly expand manufacturing and clinical work in California. Dry AMD is a common eye disorder in people over 50 caused by deterioration … Continue reading Advancing cell therapy research for dry age-related macular degeneration (dry AMD)